首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Near-infrared chemical imaging (NIR-CI) for counterfeit drug identification--a four-stage concept with a novel approach of data processing (Linear Image Signature).
【24h】

Near-infrared chemical imaging (NIR-CI) for counterfeit drug identification--a four-stage concept with a novel approach of data processing (Linear Image Signature).

机译:用于伪造药品识别的近红外化学成像(NIR-CI)-一个具有四个阶段的概念以及一种新颖的数据处理方法(线性图像签名)。

获取原文
获取原文并翻译 | 示例
           

摘要

A new stage concept was developed to reliably identify counterfeit tablets which are very similar to the genuine drug product. This concept combines single-point near-infrared spectroscopy (NIRS) and near-infrared chemical imaging (NIR-CI) with statistical variance analysis. The advantage of NIR-CI over NIRS is the potential to determine not only the amount, but also the spatial distribution of ingredients within a single tablet. Previously published NIR-CI studies used homogeneity as a key indicator for the identification of counterfeits. The state of the art approach for estimating homogeneity is to record the average and % standard deviation of predicted classification scores (i.e. concentrations) for a given component within a specimen. A disadvantage of this approach is the partial loss of spatial information. In view of this, we developed a new method using much more of the spatial information for the estimation of homogeneity. The method is based on (1) summation and unfolding of multidimensional predicted classification scores, which results in a Linear Image Signature (LIS) and (2) multivariate LIS data analysis (LIS-MVA). It could be demonstrated that this kind of NIR-CI data analysis represents an innovative approach for the identification of counterfeit tablets. Moreover, this procedure is applicable to determine the product variability, i.e. process signature of a given product thus being a valuable tool within the Quality by Design (QbD) approach of the ICH Q8 guideline.
机译:开发了一个新的阶段概念,以可靠地识别与正版药品非常相似的假冒片剂。该概念将单点近红外光谱(NIRS)和近红外化学成像(NIR-CI)与统计差异分析结合在一起。与NIRS相比,NIR-CI的优势在于不仅可以确定单个片剂中成分的数量,还可以确定其空间分布。先前发表的NIR-CI研究使用同质性作为识别假冒产品的关键指标。估计同质性的最新技术方法是记录样本中给定组分的预测分类得分(即浓度)的平均值和标准偏差%。这种方法的缺点是空间信息的部分丢失。有鉴于此,我们开发了一种使用更多空间信息来估计同质性的新方法。该方法基于(1)多维预测分类分数的求和和展开,从而得出线性图像签名(LIS)和(2)多元LIS数据分析(LIS-MVA)。可以证明,这种NIR-CI数据分析代表了一种识别假冒片剂的创新方法。而且,该程序可用于确定产品的可变性,即给定产品的过程签名,因此是ICH Q8指南的“按质量设计”(QbD)方法中的宝贵工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号